NCT02343458: A reported trial by Pearl Therapeutics, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02343458 |
|---|---|
| Title | A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 30, 2015 |
| Completion date | Aug. 31, 2017 |
| Required reporting date | Aug. 31, 2018, midnight |
| Actual reporting date | July 11, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |